Page 4 - ANWITA DEVELOPMENT TO TT
P. 4
PRODUCT EXPERTISE AND
CAPABILITIES
SOLID ORAL DOSAGE FORMS ❖ QbD Implementation for new ANDA
•Tablets & capsules, including
modified/delayed/ controlled release/ project or product development.
MUPS/ fixed-dose combinations
•Oral disintegrating tablets/films, ❖ Developing drug products with patent non-
effervescent tablets
infringing drug formulations for US,
LIQUIDS & SEMI-SOLIDS* Europe, Canada, Brazil, Africa, Singapore,
•Liquids, suspensions, syrups
•Powder for oral suspension WHO-ROW markets.
•Creams, lotions, gels, ointments
•Ophthalmic drops, Otic/nasal drops ❖ End to end product delivery support from
product identification to IP Evaluation,
STERILE INJECTABLES*
•Clear injectable solutions Formulation, Scale-up, Technology
•Pre-filled syringes
•Lyophilized powder for suspension for Transfer, BE Studies*, Registration*,
injection
•Liposomes (Micro and Nano tech) Assistance in query response, Life cycle
*Through channel partners
management and Licensing.
